Amir Heshmatpour Acquires 10,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour bought 10,000 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were bought at an average cost of $5.61 per share, for a total transaction of $56,100.00. Following the transaction, the president directly owned 3,027,000 shares in the company, valued at approximately $16,981,470. This represents a 0.33% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Neonc Technologies Stock Down 6.7%

NASDAQ NTHI traded down $0.36 during midday trading on Thursday, hitting $5.01. 51,566 shares of the company traded hands, compared to its average volume of 52,640. The company’s 50-day simple moving average is $8.71 and its 200-day simple moving average is $9.15. Neonc Technologies Holdings, Inc. has a 52 week low of $3.20 and a 52 week high of $12.99.

Institutional Investors Weigh In On Neonc Technologies

Several institutional investors have recently bought and sold shares of the company. HighPoint Advisor Group LLC boosted its holdings in shares of Neonc Technologies by 20.5% during the 4th quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company’s stock worth $9,466,000 after purchasing an additional 194,408 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Neonc Technologies by 1.0% during the 3rd quarter. Bank of America Corp DE now owns 226,486 shares of the company’s stock worth $2,056,000 after purchasing an additional 2,207 shares during the last quarter. Vanguard Group Inc. acquired a new position in Neonc Technologies in the third quarter valued at approximately $1,279,000. 683 Capital Management LLC acquired a new position in Neonc Technologies in the fourth quarter valued at approximately $442,000. Finally, Global Retirement Partners LLC acquired a new position in Neonc Technologies during the third quarter worth $434,000.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Zacks Research upgraded Neonc Technologies to a “hold” rating in a research note on Wednesday, January 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Neonc Technologies in a research note on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Neonc Technologies presently has a consensus rating of “Reduce”.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.